Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Riess, Jonathan W., Gandara, David R., Frampton, Garrett M., Madison, Russell, Peled, Nir, Bufill, Jose A., Dy, Grace K., Ou, Sai-Hong Ignatius, Stephens, Philip J., McPherson, John D., Lara, Primo N., Burich, Rebekah A., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Mack, Philip C., Schrock, Alexa B.·2018·Journal of Thoracic Oncology
DOI 10.1016/j.jtho.2018.06.019

Cited by (241)

Items 101–200 of 241

  1. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
    M.R. García Campelo, Caicun Zhou, Suresh S. Ramalingam, Huamao Mark Lin, Tae Min Kim, Gregory J. Riely, Tarek M. Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta et al. · 2022 · Journal of Clinical Medicine
  2. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
    Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Mirosław Kowalski, Regan Michelle Memmott, Ozan Yazici, Meili Sun, Catherine Shu et al. · 2026 · New England Journal of Medicine
  3. Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
    Chao Shi, Ruyue Xing, Mengmeng Li, Junnan Feng, Rui Sun, Bing Wei, Yongjun Guo, Jie Ma, Huijuan Wang · 2022 · Frontiers in Oncology
  4. First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
    Guangjian Yang, Yaning Yang, Runze Liu, Weihua Li, Haiyan Xu, Xuezhi Hao, Junling Li, Shuyang Zhang, Fei Xu, Siyu Lei et al. · 2022 · Cancer Medicine
  5. Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
    Umberto Malapelle, Sara Pilotto, Maria Lucia Reale, Francesco Passiglia, Pasquale Pisapia, Francesco Pepe, Lorenzo Belluomini, Domenico Galetta, Diego Luigi Cortinovis, Marcello Tiseo et al. · 2021 · Critical Reviews in Oncology/Hematology
  6. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
    Ikei S. Kobayashi, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Daniel Botelho Costa · 2021 · Cells
  7. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
    Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, M. Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Sayed M S Hashemi et al. · 2024 · International Journal of Molecular Sciences
  8. Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
    Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, Laura Fabbri, Renata Seminerio, Alessandro Di Federico, Eleonora Gariazzo, Silvia Costabile, Giulio Metro · 2024 · Expert Opinion on Emerging Drugs
  9. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
    Iacopo Petrini, Giuseppe Giaccone · 2022 · OncoTargets and Therapy
  10. Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
    Pascale Tomasini, Yongsheng Wang, Yongsheng Li, Enriqueta Felip, Lin Wu, Jiuwei Cui, Benjamin Besse, Alexander I. Spira, Joel W. Neal, Kōichi Goto et al. · 2025 · Journal of Clinical Oncology
  11. Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications
    T. N. Rekha, Arifullah Mohammed · 2024 · European Journal of Medicinal Chemistry
  12. Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
    Neeraj Gupta, Philippe Bernard Pierrillas, Michael J. Hanley, Steven Zhang, Paul M. Diderichsen · 2022 · CPT Pharmacometrics & Systems Pharmacology
  13. Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
    Waleed Kian, Petros Christopoulos, Areen Abu Remilah, Esther Levison, Elizabeth Dudnik, Walid Shalata, Bilal Krayim, Ranin Marei, Alexander Yakobson, Martin Faehling et al. · 2022 · Frontiers in Oncology
  14. Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
    Xin Gao, Xue‐Wu Wei, Ming-Ying Zheng, Zhi-Hong Chen, Xu‐Chao Zhang, Wen‐Zhao Zhong, Jin‐Ji Yang, Yi-Long Lung Cancer Wu, Qing Hua Zhou · 2020 · Journal of Thoracic Disease
  15. EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
    Ramakrishna R. Sompallae, Bilge Dundar, Natalya V. Guseva, Aaron Bossler, Deqin Ma · 2023 · Frontiers in Oncology
  16. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
    Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan · 2023 · Thoracic Cancer
  17. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan
    Hsin-Yi Wang, Chao‐Chi Ho, Yen‐Ting Lin, Wei‐Yu Liao, Chung‐Yu Chen, Jin‐Yuan Shih, Chong‐Jen Yu · 2024 · JCO Precision Oncology
  18. EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
    Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Shuyang Zhang, Yan Wang · 2022 · Frontiers in Pharmacology
  19. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
    James Chih‐Hsin Yang, Caicun Zhou, Pasi Antero Janne, Suresh S. Ramalingam, Tae Min Kim, Gregory J. Riely, Alexander I. Spira, Zofia Piotrowska, Tarek M. Mekhail, M.R. García Campelo et al. · 2022 · Expert Review of Anticancer Therapy
  20. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
    Liang Zeng, Lianxi Song, Li Liu, Fang Wu, Qinqin Xu, Huan Yan, Shaoding Lin, Wenjuan Jiang, Zhan Wang, Deng Li et al. · 2024 · Med
  21. Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation
    Chuanqi Xie, Jindong Kong, Fujun Miao, Xuanjun Wang, Jun Sheng · 2020 · Thoracic Cancer
  22. Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions
    Ping Yue, Mengwei Zhang, Yuanying Feng, Yuan Gao, Chao Sun, Peng Chen · 2024 · Frontiers in Oncology
  23. A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer
    Song Hu, Hao Ming, Qian He, Ming Ding, Hao Ding, Chong Li · 2024 · Frontiers in Oncology
  24. Top advances in lung cancer, 2021
    Nisha Anjali Mohindra, Jyoti D. Patel · 2022 · Cancer
  25. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
    Sai‐Hong Ignatius Ou, Huamao Mark Lin, Jin‐Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal · 2023 · Lung Cancer
  26. Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
    T. Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji et al. · 2023 · JTO Clinical and Research Reports
  27. A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer
    Bianca A. M. H. van Veggel, Anthonie J. van der Wekken, Marthe S. Paats, Lizza E.L. Hendriks, Sayed M S Hashemi, Antonios Daletzakis, Daan A. van den Broek, Linda J.W. Bosch, Kim Monkhorst, Egbert Frederik Smit et al. · 2023 · Cancer
  28. A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants
    Michael J. Hanley, Steven Zhang, Robert Griffin, Sean Xiaochun Zhu, Robert J. Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta · 2024 · Investigational New Drugs
  29. Kinase Inhibitors Involved in the Regulation of Autophagy: Molecular Concepts and Clinical Implications
    Isehaq Al‐Huseini, Srinivasa Rao Sirasanagandla, K. Suresh Babu, R. G. S. Sofin, Srijit Das · 2022 · Current Medicinal Chemistry
  30. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non–Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab
    Timothy A. Jatkoe, Songbai Wang, Justin Iver Odegaard, Anne Marie Velasco Roth, Drew Osgood, Gabriela Martinez, Paul Lucas, Joshua C. Curtin, Jayaprakash D. Karkera · 2022 · Journal of Molecular Diagnostics
  31. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
    Xiuyue Man, Xueru Sun, Chen Chen, Yan Xiang, Jing Zhang, Lei Yang · 2024 · Frontiers in Oncology
  32. Drug development and evidence for lung cancer targeted therapy in Eastern Asia
    Si‐Yang Maggie Liu, Zhen‐Yi Jin, Jia‐Yi Deng, Si-Min Zhong, Myung‐Ju Ahn, Hidehito Horinouchi, Yangqiu Li, Yi-Long Lung Cancer Wu · 2024 · The Lancet Regional Health - Western Pacific
  33. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo‐sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation
    Mei Zhao, Xuelian Li, Xin Chen · 2021 · Journal of Bioenergetics and Biomembranes
  34. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
    Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Se‐Hoon Lee · 2023 · Translational Lung Cancer Research
  35. Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming
    Haoli Liu, Jing Qin, Xinyu Qian · 2024 · Cancer Control
  36. The User’s Guide to Amivantamab
    Danielle Brazel, Janellen E. Smith, Sai‐Hong Ignatius Ou, Misako Nagasaka · 2025 · Targeted Oncology
  37. Comprehensive management strategies for amivantamab-induced toxicities and review of the literature
    Furkan Ceylan, Gamze Sönmez, Ateş Kutay Tenekeci, Ahmet Arda Unal, Mehmet Alı Nahıt Şendur · 2025 · Journal of Oncology Pharmacy Practice
  38. Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations
    Kavita Sangwan, Gaurav Agarwal · 2025 · Investigational New Drugs
  39. Deep Learning Predicts EGFR Mutation Status from Histology Images in Non–Small Cell Lung Cancer
    Jongchan Park, Sangwon Shin, Woochan Hwang, Seongho Keum, Biagio Brattoli, Jack H. Rawson, Taebum Lee, Sérgio Pereira, Chang Ho Ahn, Michael J.T. Senior et al. · 2025 · Cancer Research Communications
  40. Factors affecting outcome in resected EGFR-mutated lung cancer
    Inger Johanne Zwicky Eide, Yngvar Nilssen, Marius Lund‐Iversen, Odd Terje Brustugun · 2022 · Acta Oncologica
  41. A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)
    Wenjian Zhu, Junping Pei, Xiaoyun Lu · 2024 · Expert Opinion on Therapeutic Patents
  42. FAM46B suppresses proliferation, migration and invasion of non-small cell lung cancer via β-catenin/MMP7 signaling
    Hongyang Sang, Song Wu, Xifang Chen, Shaofei Cheng, Qianping Li · 2019 · Translational Cancer Research
  43. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations
    Petros Christopoulos, Thibaud Prawitz, Jin‐Liern Hong, Huamao Mark Lin, Luis G. Hernandez, Shu Jin, Min Tan, Irina Proskorovsky, Jianchang Lin, Pingkuan Zhang et al. · 2023 · Lung Cancer
  44. Molecular modeling, dynamic simulation, and metabolic reactivity studies of quinazoline derivatives to investigate their anti-angiogenic potential by targeting wild EGFR wt and mutant EGFR T790M receptor tyrosine kinases
    Altaf Ahmad Shah, Nitish Kumar, Preet Mohinder Singh Bedi, Salman Akhtar · 2023 · Journal of Biomolecular Structure and Dynamics
  45. Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR -mutated Non-small Cell Lung Cancer
    Matthew Z. Guo, Kristen Ashley Marrone, Alexander I. Spira, Kristine Freeman, Susan Combs Scott · 2021 · touchREVIEWS in Oncology & Haematology
  46. Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns
    Rilan Bai, Xiao Chen, Wei Song, Huimin Tian, Jiuwei Cui · 2021 · Journal of Cancer Research and Clinical Oncology
  47. Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer
    Clémence Basse, Olfa Trabelsi‐Grati, Julien Masliah‐Planchon, Céline Callens, Maud T Kamal, Paul Fréneaux, Jerzy Klijanienko, Ivan Bièche, Nicolas Girard · 2023 · International Journal of Molecular Sciences
  48. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
    Tae Min Kim, Nicolas Girard, Grace Kah Mun Low, Jianmin Zhuo, Dae Young Yu, Yishen Yang, Maiko Murota, Cindy Thiow Koon Lim, Nora Joelle Kleinman, Byoung Chul Cho · 2023 · Acta Oncologica
  49. Current paradigm of EGFR in non-small cell lung cancer: A long way forward
    Beatriz Viesser Miyamura, Isa Mambetsariev, Jeremy Fricke, Javier Arias-Romero, Karla Cadman, Sagun Shrestha, Evan P. Pisick, Danny Nguyen, Jyoti Dhar Malhotra, Amanda Reyes et al. · 2025 · Med
  50. Targeting exon 20 insertion mutations in lung cancer
    Yaning Yang, Yan Wang · 2022 · Current Opinion in Oncology
  51. Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer
    Sun Min Lim, Jii Bum Lee, Yuko Oya, Jorn Nützinger, Ross Andrew Soo · 2023 · JCO Oncology Practice
  52. Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
    Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu · 2023 · Clinical Lung Cancer
  53. Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report
    Yaping Zhang, Hui Wang, Xiaoyan Wang, Shuai Li, Hongming Fang · 2021 · Clinical Lung Cancer
  54. Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
    Lingling Zhu, Yanyang Liu, Honglin Gao, Jiewei Liu, Qinghua Zhou, Feng Luo · 2022 · Frontiers in Cell and Developmental Biology
  55. Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
    Lifeng Wang, Zichen Liu, Zhiyi Wan, Dong Jiang, Min Zhang, Shuku Liu, Nanying Che · 2022 · Annals of Translational Medicine
  56. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Xue Yang, Jun Zhao · 2022 · PubMed Central
  57. Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations
    Petros Christopoulos, Nicolas Girard, Claudia Proto, Marta Soares, Pilar Garrido, Anthonie J. van der Wekken, Sanjay Popat, Joris Diels, Claudio A. Schioppa, Jan Sermon et al. · 2023 · Cancers
  58. Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion
    Yue Zheng, Yang Fu, Yueyun Chen, Qing Li, Ting Liu, Zhenyu Ding · 2023 · Current Oncology
  59. Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation
    Yuequan Shi, Yan Xu, Mengzhao Wang · 2024 · BMC Cancer
  60. Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients
    Mónica Garzón‐Ibáñez, Roxana Reyes, Miguel Ángel Molina‐Vila, Ivana Sullivan · 2025 · Clinical & Translational Oncology
  61. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021
    Esin Aysel Kandemir · 2022 · Journal of Oncology Pharmacy Practice
  62. Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
    Abram Arnold, Apar Kishor Ganti · 2023 · OncoTargets and Therapy
  63. Race-Associated Genomic Correlates of Therapeutic Response in African American Patients With Non–Small-Cell Lung Cancer
    Pin Li, Kaitlyn Kane, Frank M. Wolf, Anna Belinda Berry, Shirish M. Gadgeel, Amanda B. Pilling · 2023 · JCO Precision Oncology
  64. Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations
    Wei Heng, Chuanyun You, Cai Shangli, Qi Chuang, Mingzhe Xiao · 2019 · Lung Cancer
  65. Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study
    Thomas Pierret, Laurent Greillier, Florian Guisier, Catherine Daniel, R. Descourt, Loïck Galland, Olivier Molinier, Chantal Decroisette, Alexis Benjamin Cortot, Diane Moreau et al. · 2025 · Lung Cancer
  66. Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study
    Jin−Ji Yang, Yu Mu, Zhehai Wang, Jianchun Duan, Tao Zhang, Lin Wu, Hua Zhong, Jun Zhao, Yu Yao, Ping Wang et al. · 2025 · Journal of Thoracic Oncology
  67. Targeted next generation sequencing (NGS) enables identification of rare EGFR exon-20 insertion (p.H773_V774insPHPH) in lung adenocarcinoma patient
    Prerana Jha, Vaishakhi Trivedi, Pooja Mahesh Kulkarni, Simran Rai, Minit Jalan Shah, Pratik Chandrani, Anuradha Bharat Choughule, Venkataramanan Ramachandran, Vanita Noronha, Kumar Prabhash et al. · 2023 · Medical Reports
  68. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation
    Ruiying Zhao, Jiaqi Li, Lianying Guo, Chan Xiang, Shengnan Chen, Jikai Zhao, Jinchen Shao, Lei Zhu, Min Ye, Gang Qin et al. · 2024 · Targeted Oncology
  69. Identification of a transcription factor‑cyclin family genes network in lung adenocarcinoma through bioinformatics analysis and validation through RT‑qPCR
    Xiaodong Yang, Yongjia Zhou, Haibo Ge, Zhongxian Tian, Peiwei Li, Xiaogang Zhao · 2022 · Experimental and Therapeutic Medicine
  70. Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies
    Wenqian Li, Rilan Bai, Hanfei Guo, Jiuwei Cui · 2023 · Chinese Medical Journal
  71. EGFR amplification indicated poor prognosis in EGFR‐mutated lung cancer with leptomeningeal metastases
    Di Geng, Ruina Niu, Jinghong Li, Sanxing Guo, Qianqian Guo, Siyuan Huang, Yurong Wang, Xingya Li · 2024 · The Clinical Respiratory Journal
  72. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study
    Weirui Wu, Silin Yu, Jinsheng Huang, Qi Qi, Yongyi Wu, Jun Dong · 2024 · BMC Cancer
  73. Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway
    Xiangdan Cuan, Xingying Yang, Jinxian Wang, Jun Sheng, Xuanjun Wang, Yanping Huang · 2024 · Bioorganic Chemistry
  74. The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
    Fenneke Zwierenga, L. Zhang, Josef Melcr, Ed M. D. Schuuring, Bianca A. M. H. van Veggel, Adrianus Johannes de Langen, Harry J.M. Groen, Matthew R. Groves, Anthonie J. van der Wekken · 2024 · Lung Cancer
  75. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations].
    Wenxing Du, Yang Wo, Tong Lu, Yuanyong Wang, Wenjie Jiao · 2019 · PubMed Central
  76. Case report: sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients
    Ruilin Wang, Yu Sheng, Limeng Yu, Jiuzhou Zhao, Shuyue Jiao, Qiming Wang, Yufeng Wu · 2022 · Translational Cancer Research
  77. Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations
    Hanifeh Mirtavoos‐Mahyari, Elham Rismani, Alireza Sarkar Lotfabadi, Azizollah Abbasi Dezfouli, Kambiz Sheikhy, Mojtaba Mokhber Dezfuli, Jalal Heshmatnia · 2021 · BioMolecular Concepts
  78. Classification of atypical EGFR mutations in non-small-cell lung cancer
    Rafael Rosell, Andrés Felipe Cardona, Oscar G. Arrieta, María González‐Cao · 2022 · Annals of Oncology
  79. Molecular Testing in Lung Cancer
    Alain Borczuk · 2023 · Surgical pathology clinics
  80. EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics
    Naoki Furuya · 2025 · Future Oncology
  81. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
    Rachel E. Sanborn, Caicun Zhou, Kejing Tang, Byoung Chul Cho, Susanna Yee-Shan Cheng, Sanjay Popat, Akira Ono, Shun Lu, Margarita Majem, Andrés Aguilar et al. · 2025 · Targeted Oncology
  82. Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression
    Rashmi Shah, Gopal P. Pathak, John Fris, Mathieu Castonguay, Tanya L. Gillan, Michael D. Carter, Zhaolin Xu · 2026 · European Journal of Cancer
  83. Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non–Small-Cell Lung Cancer and Other Cancer Types
    Yan Yin, Lijie Song, Dongsheng Shi, Bin Liu, Xiangke Li, Minjie Yang, Bihao Liu, Dejuan Wang, Jianwen Qin · 2022 · JCO Precision Oncology
  84. [Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
    2023 · PubMed Central
  85. Clinical and economic benefits of using next-generation sequencing in the diagnostics of patients with non-small cell lung cancer with rare mutations
    Katarzyna Magdalena Stencel, Bartosz Wasąg, Cezary Pruszko, Krystyna Dąbrowska, Paweł Książek, Karolina Dziadek, Maciej Bryl, Maciej Jerzy Krzakowski · 2023 · Oncology in Clinical Practice
  86. Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutation: a report of two cases
    Qiang Luo, Leichong Chen, Zhenyu Li, Li Cheng, Sijia Zhang, Yan Zong, Qianwen Li, Kenichi Suda, Mariacarmela Santarpía, Samir M. Dalia et al. · 2023 · Translational Lung Cancer Research
  87. The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2
    Man-San Zhang, Yi‐Chen Yeh, Hsien‐Neng Huang, Long-Wei Lin, Yen-Lin Oscar Huang, Lei‐Chi Wang, Lai-Jin Yao, Tze-Chun Hung, Yu‐Fen Tseng, Yi‐Hsuan Lee et al. · 2024 · PLoS ONE
  88. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions
    Haibo Wang, Yiquan Xu, Jinlan Lin, Yunjian Huang · 2024 · Cancer Control
  89. EGFR exon 20 insertion in non-small cell lung cancer
    Goutam Santosh Panda, Vanita Noronha, Omshree Anil Shetty, Subhash C. Yadav, Rajiv Kumar, Vijay Patil, Pratik Chandrani, Amit Janu, Abhishek Mahajan, Anuradha Chougule et al. · 2022 · Cancer Research Statistics and Treatment
  90. The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation
    Jianghao Ren, Ruijun Liu · 2023 · Methods in molecular biology
  91. Prognostic outcomes and recurrence patterns in resected stage I lung adenocarcinoma harbouring atypical epidermal growth factor receptor mutations
    Tao Chen, Jialiang Wen, Yingze Li, Jiajun Deng, Yifan Zhong, Likun Hou, Yunlang She, Dong Xie, Chang Chen · 2023 · European Journal of Cardio-Thoracic Surgery
  92. The Workflow for Computational Analysis of Single-cell RNA-sequencing Data
    Sung-Hun Woo, Byung Chul Jung · 2024 · Korean Journal of Clinical Laboratory Science
  93. Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China
    Lan Shen, Guangyuan Hu, Yan Wang, Jing Zhao, Xin Li, Jianmin Zhuo, Grace Kah Mun Low, Shun Lu · 2025 · BMC Pulmonary Medicine
  94. Efficacy of Almonertinib Versus Osimertinib as the First‐Line Treatment for Non‐Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study
    Xiujing Yao, Ruyue Li, Xue Dong, Ying Li, Yintao Li · 2025 · Cancer Medicine
  95. Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non–Small Cell Lung Cancer: A Case Report
    Daisuke Morinaga, Megumi Furuta, Doppo Fukui, Yuki Matsuura, Yukiko Yoshida, Shotaro Ito, Yuta Takashima, Hidenori Kitai, Zenichi Tanei, J. Sakakibara-Konishi et al. · 2026 · Clinical Lung Cancer
  96. EGFR Exon 20 Insertion–Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions
    Li Yieng Lau, Noor Rashidha Binte Meera Sahib, Carina Ysha P. Cangco, Aaron C. Tan · 2026 · Drugs
  97. Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors
    Ximeng Liu, Moses H. Stamboulian, Maxime Borgeaud, Erjia Zhu, Caroline M. Weipert, Nicole Zhang, Monique B. Nilsson, Kaiwen Wang, Lingzhi Hong, Jinghao Wang et al. · 2026 · Journal of Thoracic Oncology
  98. Amivantamab in advanced non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real‐world data from the Italian ATLAS Registry
    Francesco Passiglia, Antonio Passaro, Eleonora Gariazzo, Michele Montrone, Giulia Pasello, Marcello Tiseo, Marco Russano, Fabrizio Citarella, Lucia Anna Muscarella, Daniele Pozzessere et al. · 2026 · Cancer
  99. Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies
    Junfeng Guo, Qiuyuan Wen, Songqing Fan · 2026 · MedComm
  100. Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies
    Lizza E.L. Hendriks, Jessica J Lin, Daniel S.W. Tan, Fabian Acker, Francesca Rita Ogliari, May‐Lucie Meyer, David Planchard, Martin Reck · 2026 · The Lancet Respiratory Medicine